Nls Pharmaceutics Ag Stock Today
| NLSP Stock | USD 3.43 0.06 1.78% |
Performance0 of 100
| Odds Of DistressOver 81
|
NLS Pharmaceutics is selling at 3.43 as of the 22nd of November 2024; that is 1.78 percent increase since the beginning of the trading day. The stock's last reported lowest price was 3.33. NLS Pharmaceutics has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for NLS Pharmaceutics AG are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 3rd of December 2022 and ending today, the 22nd of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 29th of January 2021 | Category Healthcare | Classification Health Care |
NLS Pharmaceutics AG, a biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company was incorporated in 2015 and is based in Zurich, Switzerland. Nls Pharmaceutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 3.82 M outstanding shares of which 22.55 K shares are now shorted by private and institutional investors with about 0.83 trading days to cover. More on NLS Pharmaceutics AG
Moving together with NLS Stock
| 0.77 | ME | 23Andme Holding | PairCorr |
| 0.86 | VALN | Valneva SE ADR | PairCorr |
| 0.67 | JNJ | Johnson Johnson Sell-off Trend | PairCorr |
Moving against NLS Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
NLS Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO President | Alexander MBA | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation | |||||
Debt LevelsNLS Pharmaceutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand NLS Pharmaceutics' financial leverage. It provides some insight into what part of NLS Pharmaceutics' total assets is financed by creditors.
| |||||
NLS Pharmaceutics AG (NLSP) is traded on NASDAQ Exchange in USA. It is located in The Circle 6, Zurich, Switzerland, 8058 and employs 7 people. NLS Pharmaceutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 12.84 M. NLS Pharmaceutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 3.82 M outstanding shares of which 22.55 K shares are now shorted by private and institutional investors with about 0.83 trading days to cover.
NLS Pharmaceutics AG currently holds about 1.35 M in cash with (9.68 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.08.
Check NLS Pharmaceutics Probability Of Bankruptcy
Ownership AllocationThe market capitalization of NLS Pharmaceutics AG is $12.84 Million. NLS Pharmaceutics AG holds noticeable amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check NLS Ownership Details
NLS Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Bvf Inc | 2024-09-30 | 143.7 K | |
| Citadel Advisors Llc | 2024-06-30 | 136.3 K | |
| Hrt Financial Llc | 2024-06-30 | 16.8 K | |
| Bank Of America Corp | 2024-06-30 | 90.0 | |
| Renaissance Technologies Corp | 2024-09-30 | 0.0 | |
| Geode Capital Management, Llc | 2024-06-30 | 0.0 |
NLS Pharmaceutics Historical Income Statement
NLS Stock Against Markets
NLS Pharmaceutics Corporate Management
| Sharon Keys | Head Affairs | Profile | |
| iur LLM | G Counsel | Profile | |
| Chad MBA | Chief Officer | Profile | |
| Elena ThyenPighin | Chief Officer | Profile | |
| George MD | Chief Development | Profile |
Additional Tools for NLS Stock Analysis
When running NLS Pharmaceutics' price analysis, check to measure NLS Pharmaceutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NLS Pharmaceutics is operating at the current time. Most of NLS Pharmaceutics' value examination focuses on studying past and present price action to predict the probability of NLS Pharmaceutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NLS Pharmaceutics' price. Additionally, you may evaluate how the addition of NLS Pharmaceutics to your portfolios can decrease your overall portfolio volatility.